Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2018
Price : $35 *
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Aug 2016.
- 06 Jun 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2016.